Life Biosciences is focused on developing innovative cellular rejuvenation therapies aimed at reversing and preventing diseases associated with aging. The company targets the biological mechanisms of aging, which have been shown to be modifiable through scientific research. Their approach includes two core platforms: the Partial Epigenetic Reprogramming Platform and the Chaperone-Mediated Autophagy Platform. The former utilizes Yamanaka factors to reprogram the epigenome of older organisms, demonstrating promising results in restoring visual function and nerve regeneration in various animal models. The latter platform enhances the degradation of unwanted proteins in cells, addressing the decline in chaperone-mediated autophagy that occurs with aging, and has shown efficacy in preclinical models of neurodegenerative diseases.

The technologies developed by Life Biosciences are grounded in cutting-edge research from leading scientists and aim to address critical unmet medical needs related to aging. The Partial Epigenetic Reprogramming Platform has shown potential in restoring vision and nerve function, while the Chaperone-Mediated Autophagy Platform focuses on increasing the activity of cellular processes that degrade harmful protein aggregates. Both platforms represent a significant advancement in the therapeutic landscape for age-related diseases, offering new avenues for treatment where few options currently exist.

United States

Life Biosciences is dedicated to developing novel therapies to extend healthy human lifespan by targeting the biological causes of aging. Founded in 2017 and headquartered in Boston, MA, we are pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Our platform approach enables us to develop medicines with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical
unmet needs.

Life Biosciences

Company Details